Premium
Anti‐transcriptional intermediary factor 1‐γ antibody as a biomarker in patients with dermatomyositis
Author(s) -
Shimizu Kyoko,
Kobayashi Tadahiro,
Kano Miyu,
Hamaguchi Yasuhito,
Takehara Kazuhiko,
Matsushita Takashi
Publication year - 2020
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.15128
Subject(s) - dermatomyositis , medicine , gastroenterology , antibody , interstitial lung disease , malignancy , biomarker , endocrinology , immunology , lung , biology , biochemistry
The presence of anti‐transcriptional intermediary factor (TIF)1‐γ antibody (Ab) is associated with cancer in adult patients with clinically amyopathic dermatomyositis (CADM) or dermatomyositis (DM). In this study, we examined whether anti‐TIF1‐γ Ab levels are associated with disease activity in patients with CADM/DM. Anti‐TIF1‐γ Ab levels were examined in 23 patients with CADM or DM (CADM, n = 6; DM, n = 17). Baseline characteristics and outcomes were recorded, and serial measurements of anti‐TIF1‐γ Ab levels were obtained. Of the 23 patients with detectable anti‐TIF1‐γ Ab, 16 (70%) had an internal malignancy, while two (9%) had interstitial lung disease. Mean initial anti‐TIF1‐γ Ab levels (134 ± 47 index) were significantly decreased after 24 months (54 ± 45 index, P < 0.0001) and remained decreased thereafter. Anti‐TIF1‐γ Ab became negative (index value, <32) in 10 patients (43%) and remained positive (index value, ≥32) in 13 patients (57%) during the clinical course. The frequency of remission in the anti‐TIF1‐γ Ab‐negative conversion group (100%) was significantly higher than in the sustained positive group (0%, P < 0.0001). Furthermore, mortality in the anti‐TIF1‐γ Ab‐negative conversion group (0%) was significantly lower than that in sustained positive group (69%, P < 0.001). This study indicates that anti‐TIF1‐γ Ab levels are a useful and relevant surrogate marker of disease activity during follow‐up monitoring.